Inhibition of carcinogenesis by retinoids.
Retinoids are effective inhibitors of chemical carcinogenesis in the mammary gland and urinary bladder of experimental animals. Modification of the basic retinoid structure has produced retinoids with increased target organ specificity, resulting in increased anticancer activity with reduced systemic toxicity. Combining retinoid treatment with hormonal manipulation results in a synergistic inhibition of mammary carcinogenesis; this combination approach also inhibits development of additional mammary cancers following surgical removal of the first mammary cancer. Retinoids are most effective when administered shortly after the carcinogenic insult. However, even when retinoid treatment is delayed, the compounds are still effective cancer chemopreventive agents for the mammary gland and urinary bladder. The length of time that retinoid exposure can be delayed and retain an anticancer effect is directly related to tumor latency, with a longer delay permissible against tumors with long latent periods.
D000230:Adenocarcinoma / Q000139:chemically induced* / Q000601:surgery; D000818:Animals; D002273:Carcinogens / Q000633:toxicity*; D002369:Castration; D004347:Drug Interactions; D004357:Drug Synergism; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000517:prevention & control* / Q000601:surgery; D051381:Rats; D011919:Rats, Inbred Strains; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000517:prevention & control; D014801:Vitamin A / Q000031:analogs & derivatives* / Q000494:pharmacology
D002273:Carcinogens; D014801:Vitamin A